for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding AG

ROG.S

Latest Trade

348.80CHF

Change

1.20(+0.35%)

Volume

168,669

Today's Range

346.75

 - 

349.80

52 Week Range

290.55

 - 

359.10

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
347.60
Open
348.80
Volume
168,669
3M AVG Volume
24.96
Today's High
349.80
Today's Low
346.75
52 Week High
359.10
52 Week Low
290.55
Shares Out (MIL)
854.26
Market Cap (MIL)
305,103.40
Forward P/E
17.53
Dividend (Yield %)
--

Next Event

Roche Holding AG at Redburn Gene Therapy Virtual Summit

Latest Developments

More

Roche CEO says demand for COVID-19 tests set to decline in H2

Roche Says FDA Grants Breakthrough Therapy Designation For Venclexta In Combination With Azacitidine

Japan Becomes First Country To Approve Regeneron Antibody Cocktail For The Treatment Of Mild To Moderate Covid-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry

Major Drugs

Contact Info

Grenzacherstr. 124

4058

Switzerland

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial and Information Officer

Cristina A. Wilbur

Member of the Corporate Executive Committee, Head Group Human Resources

Key Stats

2.17 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2018

56.8K

2019

61.5K

2020

58.3K

2021(E)

61.3K
EPS (CHF)

2018

18.140

2019

20.160

2020

19.160

2021(E)

19.784
Price To Earnings (TTM)
21.40
Price To Sales (TTM)
5.11
Price To Book (MRQ)
7.85
Price To Cash Flow (TTM)
15.69
Total Debt To Equity (MRQ)
39.70
LT Debt To Equity (MRQ)
29.84
Return on Investment (TTM)
26.07
Return on Equity (TTM)
17.62

Latest News

Latest News

COVID-19 tests boost Roche sales but demand expected to weaken

Swiss drugmaker Roche said on Thursday that strong demand for COVID-19 tests had helped it rebound from a weak start to the year, as it posted better-than-expected sales for the first half.

Roche in talks with FDA on Alzheimer's candidate, says CEO

Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.

Roche keeps outlook as diagnostics power sales growth

Roche posted first-half net profit of 8.22 billion Swiss francs ($8.96 billion) as sales rose 8% at constant exchange rates to a better-than expected 30.71 billion francs.

Roche to cut 300-400 product development jobs - Blick

Roche plans to cut 300-400 jobs this year at product development (PD) sites, company executives including Chief Medical Officer Levi Garraway said during a recorded video call with employees obtained by Swiss newspaper Blick.

Novartis contends Roche 'unjustly enriched' itself with $210 million in fees -lawsuit

Novartis AG wants Roche Holding AG to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.

Novartis fights Roche in $210 mln U.S. dispute over licensing fees

Novartis wants Roche to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a U.S. District Court lawsuit.

Roche's neuromyelitis optica drug Enspryng wins EU approval

Roche's Enspryng has been approved by the European Commission, the Swiss drugmaker said on Monday, the latest regulatory blessing for the injectible drug that can be given at home to treat neuromyelitis optica spectrum disorder.

U.S. approves Roche drug for emergency use against severe COVID-19

U.S. health regulators have approved Roche's arthritis drug Actemra for emergency use to treat hospitalized COVID-19 patients, giving an extra boost to a medicine that was already allowed to be administered on compassionate grounds.

Roche COVID test receives U.S. greenlight for asymptomatic people

Roche's cobas SARS-CoV-2 Test has received U.S. authorisation for testing individuals without symptoms or reasons to suspect a COVID-19 infection, the Swiss drugmaker said on Tuesday.

Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

RPT-UPDATE 1-Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

UPDATE 1-Roche test boss says COVID rapid test effectiveness to wane as shots increase

Rapid COVID-19 tests that have become a key part of nations' COVID-19 detection strategies will grow less effective as more people get vaccinated, Roche diagnostics chief Thomas Schinecker said on Tuesday.

Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases

New late-stage trial data show Regeneron and Roche's antibody cocktail against COVID-19 cut hospitalisation or death by 70% versus a placebo in non-hospitalised patients, the Swiss drugmaker said on Tuesday.

Roche antibody cocktail shown effective in COVID-19 patients

New late-stage clinical trial data show an antibody cocktail of casirivimab and imdevimab reduced hospitalisation or death by 70% versus a placebo in non-hospitalised patients with COVID-19, Swiss drugmaker Roche Holding said on Tuesday.

European shares flat as financials, miners weigh; Flutter rises

European stocks ended flat on Monday, with declines led by financial and mining stocks, while gains in betting firm Flutter Entertainment and optimism about a strong economic rebound helped limit losses.

Roche buys GenMark for $1.8 million to challenge test rivals

Roche is filling a testing portfolio gap by buying U.S.-based GenMark Diagnostics in a $1.8 billion deal that the Swiss pharmaceuticals manufacturer said taps one of the fastest-growing diagnostics areas.

Roche obtains $43 mln settlement in rebate fraud case

Healthcare conglomerate Roche has secured a $43 million settlement from pharmacy network Priority Healthcare Corp and associated entities and individuals, which Roche had accused of engaging in an insurance fraud scheme involving its Accu-Chek diabetes test strips.

Roche to boost monthly COVID-19 PCR test production to 70 mln by July

Roche will double monthly production of PCR tests to detect active COVID-19 infections to 40 million in the first quarter and roughly 70 million by July, its diagnostics chief said on Thursday.

Roche sees 2021 growth, buoyed by COVID tests as pandemic persists

Roche Chief Executive Severin Schwan expects COVID-19 test demand to continue to surge, buoying the Swiss drug and diagnostics maker's forecast to lift 2021 sales and profit despite pressure on its main drugs business.

Roche gets EU green light for influenza treatment Xofluza

Swiss drugmaker Roche said the European Commission approved its Xofluza to treat influenza in patients aged 12 years and above, the first new influenza antiviral for patients in almost 20 years, Roche said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up